Coya Therapeutics, Inc. Announces Peer-Reviewed Publication of Phase 2a Clinical Trial Data for COYA 101 in Amyotrophic Lateral Sclerosis (ALS)
Retrieved on:
Thursday, September 1, 2022
Amyotrophic lateral sclerosis, Inflammation, Neuroinflammation, Patient, COVID-19, HIV disease progression rates, Houston Methodist Hospital, Safety, Therapy, Protein, DB, Disease, ITT, Open-label trial, Phenotype, COYA, Particle-size distribution, OLR1, Disability, GLOBE, FTD, Exosome, Neuro, Coronavirus Scientific Advisory Board (Turkey), Biomarker, Oxidative stress, ALS, OLE, Medical device, Pharmaceutical industry, Person, Regulatory T cell, Regulatory T cell, Neuroimmunology, Scleroderma, Fibrosis
Coya has an exclusive worldwide license from Houston Methodist Hospital to develop, manufacture, and commercialize COYA 101.
Key Points:
- Coya has an exclusive worldwide license from Houston Methodist Hospital to develop, manufacture, and commercialize COYA 101.
- Subjects enrolled in the Phase 2a trial were initially randomized into a double-blind portion to receive active Treg cells or matching placebo every four weeks over 24 weeks.
- The DB portion of the trial was curtailed due to COVID-19-related restrictions, and the limited number of patients enrolled made statistical analysis not feasible.
- The Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) is a validated rating instrument that gauges the progression of disability in patients with amyotrophic lateral sclerosis (ALS) on a 48-point scale.